References

Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

10.1097/nen.0b013e31824b211b · 2012 · External reference

CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis.

10.1016/s1474-4422(16)00070-3 · 2016 · External reference

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease.

10.1002/ana.1054 · 2001 · External reference

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis.

10.1515/cclm.2011.086 · 2011 · External reference

Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B.

10.1002/ana.20009 · 2004 · External reference

Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia.

10.1001/jama.2019.2000 · 2019 · External reference

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

10.1001/jama.2015.4669 · 2015 · External reference

Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial.

10.1001/jamaneurol.2023.0997 · 2023 · External reference

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease.

10.1093/brain/awac333 · 2023 · External reference

Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology.

10.1001/jamaneurol.2023.5319 · 2024 · External reference

Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders.

10.1001/jama.2020.12134 · 2020 · External reference

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

10.1016/s1474-4422(21)00214-3 · 2021 · External reference

A head-to-head comparison of plasma biomarkers to detect Alzheimer’s disease in a memory clinic.

10.1002/alz.14609 · 2025 · External reference

Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform.

10.1038/s41591-025-03622-w · 2025 · External reference

Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests.

10.1038/s41591-024-02869-z · 2024 · External reference

Blood biomarkers to detect Alzheimer disease in primary care and secondary care.

10.1001/jama.2024.13855 · 2024 · External reference

A multicentre validation study of the diagnostic value of plasma neurofilament light.

10.1038/s41467-021-23620-z · 2021 · External reference

Acceptable performance of blood biomarker tests of amyloid pathology—recommendations from the Global CEO Initiative on Alzheimer’s Disease.

10.1038/s41582-024-00977-5 · 2024 · External reference

Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings.

10.1002/alz.70535 · 2025 · External reference

Evidence gap in blood biomarkers for Alzheimer’s disease.

10.1136/bmj-2025-084781 · 2025 · External reference

Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration.

10.1186/s13195-024-01474-z · 2024 · External reference

Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer’s disease.

10.1002/alz.13026 · 2023 · External reference

Acceptability and feasibility of plasma phosphorylated-tau181 in two memory services.

10.1002/gps.5897 · 2023 · External reference

A two-step workflow based on plasma p-tau217 to screen for amyloid ß positivity with further confirmatory testing only in uncertain cases.

10.1038/s43587-023-00471-5 · 2023 · External reference

Diagnostic performance and clinical applicability of blood-based biomarkers in a prospective memory clinic cohort.

10.1212/wnl.0000000000201597 · 2023 · External reference

A neurologist’s perspective on serum neurofilament light in the memory clinic: a prospective implementation study.

10.1186/s13195-021-00841-4 · 2021 · External reference

Clinical utility of an Alzheimer’s disease blood test among cognitively impaired patients: results from the Quality Improvement PrecivityAD2 (QUIP II) clinician survey study.

10.3390/diagnostics15020167 · 2025 · External reference

A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment.

10.1002/acn3.51863 · 2023 · External reference

Optimising Alzheimer’s disease diagnosis and treatment: assessing cost-utility of integrating blood biomarkers in clinical practice for disease-modifying treatment.

10.14283/jpad.2024.67 · 2024 · External reference

Disclosure of plasma p-tau217 measure improves diagnostic confidence in patients with Alzheimer’s disease versus syndromes associated with frontotemporal lobar degeneration.

10.1002/alz.70289 · 2025 · External reference

CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials.

10.1001/jama.2025.4347 · 2025 · External reference

Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability.

10.1038/s43587-024-00731-y · 2024 · External reference

Plasma phosphorylated tau 217 to identify preclinical Alzheimer disease.

10.1001/jamaneurol.2025.3217 · 2025 · External reference

Testing for Alzheimer disease biomarkers and disclosing results across the disease continuum.

10.1212/wnl.0000000000206891 · 2023 · External reference

Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays.

10.1002/alz.12841 · 2023 · External reference